Literature DB >> 33164137

Reply to Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".

William V Padula1,2, Sonal Parasrampuria3, Mariana P Socal3, Rena M Conti4, Gerard F Anderson3.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 33164137      PMCID： PMC7721406          DOI： 10.1007/s40273-020-00973-9

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

1.  Comment on "Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US".

Authors:  Richard Manning
Journal:  Pharmacoeconomics       Date:  2020-11-09       Impact factor: 4.981

2.  Modifying the Criteria for Granting Orphan Drug Market Exclusivity.

Authors:  Mariana P Socal; Sonal Parasrampuria; Gerard F Anderson
Journal:  Value Health       Date:  2020-09-28       Impact factor: 5.725

3.  Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US.

Authors:  William V Padula; Sonal Parasrampuria; Mariana P Socal; Rena M Conti; Gerard F Anderson
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.